Aclarion, Inc. (ACON)
$
7.28
-0.04 (-0.55%)
Key metrics
Financial statements
Free cash flow per share
-26.5363
Market cap
4.2 Million
Price to sales ratio
77.6246
Debt to equity
0
Current ratio
21.6833
Income quality
0.8360
Average inventory
0
ROE
-1.2690
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aclarion, Inc., a healthcare technology company, specializes in developing software applications for magnetic resonance spectroscopy (MRS) across the United States. The company offers the NOCISCAN-LS Post-Processor suite, which includes NOCICALC-LS, designed to receive and process acquired disc MRS data to calculate levels of degenerative pain biomarkers, as well as NOCIGRAM-LS, a clinical decision support software. Founded in 2008 and based in San Mateo, California, Aclarion, which was previously known as Nocimed, Inc. before rebranding in December 2021, has its earnings per share (EPS) reported at -$7,480.21 indicating the company's profitability on a per-share basis. The total costs and expenses for the company amount to $5,558,770.00 reflecting its overall spending. Furthermore, the cost of revenue is $129,767.00 showcasing its production and operational expenses. The EBITDA is -$6,264,322.00 a key indicator of the company's operational profitability; however, the company reported a net loss of -$6,992,927.00 indicating challenges within its operations. The stock is affordable at $7.33 making it suitable for budget-conscious investors. With an average trading volume of 14,235.00 the stock indicates moderate liquidity in the market. Aclarion, Inc. has a market capitalization of $4,238,380.00 categorizing it as a small-cap player in the financial arena. As a significant participant in the Medical - Healthcare Information Services industry, the company contributes immensely to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is Aclarion, Inc. (ACON) a good investment?
Investing in Aclarion, Inc. (ACON) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Aclarion, Inc. (ACON)'s stock forecast?
Analysts predict Aclarion, Inc. stock to fluctuate between $6.20 (low) and $3,500.42 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aclarion, Inc.'s market capitalization?
As of 2025-08-19, Aclarion, Inc.'s market cap is $4,238,380, based on 582,371 outstanding shares.
How does Aclarion, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aclarion, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aclarion, Inc. (ACON) stock?
To buy Aclarion, Inc. (ACON) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACON. Place an order (Market, Limit, etc.).
What is the best time to invest in Aclarion, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Aclarion, Inc. stock ever split?
Aclarion, Inc.'s last stock split was 1:27 on 2025-03-28.
How did Aclarion, Inc. perform in the last earnings report?
Revenue: $45,724 | EPS: -$7,480.21 | Growth: -86.14%.
Where can I find Aclarion, Inc.'s investor relations reports?
Visit https://www.aclarion.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aclarion, Inc.?
You can explore historical data from here
What is the all-time high and low for Aclarion, Inc. stock?
All-time high: $21,708 (2022-04-27) | All-time low: $0.61 (2025-03-14).
What are the key trends affecting Aclarion, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prismmediawire.com
BROOMFIELD, Colo., August 05, 2025 – PRISM MediaWire – Aclarion, Inc.
globenewswire.com
Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first time and expects continued QOQ growth for the remainder of the year Cost-effectiveness analysis demonstrating Nociscan is more effective and less costly than provocative discography published in peer-reviewed journal adding critical evidence in support of payer coverage Pivotal CLARITY trial proceeding on schedule with first patient enrolled to validate Nociscan's ability to improve surgical outcomes for chronic low back pain, with internal interim results expected in Q2 2026 Reaffirms cash runway through Q3 2026 to prove out the key catalysts of demonstrating significant scan volume growth and visibility into the success of CLARITY BROOMFIELD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that scan volume has achieved significant year over year growth of 132% from 2Q24 to 2Q25 and has demonstrated two consecutive quarters of growth for the first time.
globenewswire.com
The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY expected in Q2 2026 BROOMFIELD, Colo., June 25, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the first patient enrollment in the CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial evaluating Nociscan's clinical and economic value in spine surgery.
globenewswire.com
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Keck Medical Center of USC as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.
globenewswire.com
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of the Texas Back Institute (TBI) as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.
globenewswire.com
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Advocate Aurora Research Institute, part of Advocate Health, as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) site.
globenewswire.com
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, LA.
globenewswire.com
BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.
globenewswire.com
Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates.
globenewswire.com
BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review.
See all news
